MENU
JUN 20, 2019 9:00 AM PDT

Keynote Presentation: Transforming Drug Discovery with Precision Medicine

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Post Doctoral Research Scholar at University of California, San Francisco
    Biography
      Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer.

      Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.

    Abstract

    Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the efficacy and safety of many marketed therapeutic agents, still the drug discovery process is still slowly evolving. In oncology, the concept of precision medicine is being utilized to accelerate the drug discovery process by patient/disease stratifications. Moreover, several drugs discoveries programs are gaining accelerated approval for rare/orphan diseases of unmet medical need. 

    Using precision medicine many attempts are made to differentiate the responder from non-responders via genetic predictors. The success of patient stratification is solely based on genomic driver-based stratification. Additionally, precision medicine-based approaches with genomic analysis can reveal the mechanism of therapy failure. Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance, and resistance, especially in the absence of pre-existing subclones, remains unclear. Moreover, using technologies that enable precision medicine we can elucidate rational combination therapy to alter tumor microenvironment and alter tumor resistance.

    Learning Objectives: 

    1. Use cases of precision medicine in the drug discovery process
    2. Accelerating the drug discovery process through precision combinatorial therapy to modulate therapy resistance


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources